Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 586,941 shares, a growth of 129.5% from the January 29th total of 255,701 shares. Approximately 3.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 256,977 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily trading volume, of 256,977 shares, the days-to-cover ratio is presently 2.3 days. Approximately 3.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MRKR. Jane Street Group LLC purchased a new stake in Marker Therapeutics in the 2nd quarter valued at about $33,000. Virtu Financial LLC bought a new stake in shares of Marker Therapeutics during the third quarter valued at approximately $25,000. Two Sigma Investments LP bought a new stake in shares of Marker Therapeutics during the third quarter valued at approximately $33,000. Boyer Financial Services Inc. purchased a new stake in shares of Marker Therapeutics in the fourth quarter valued at approximately $57,000. Finally, XTX Topco Ltd grew its stake in Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares in the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright assumed coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.17.

Marker Therapeutics Trading Down 6.3%

Shares of NASDAQ MRKR traded down $0.10 during midday trading on Friday, hitting $1.48. The company’s stock had a trading volume of 65,351 shares, compared to its average volume of 192,462. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07. The firm has a market cap of $24.67 million, a P/E ratio of -1.20 and a beta of 1.44. The business’s 50 day moving average is $1.66 and its two-hundred day moving average is $1.27.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.